Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Background The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low‐density lipoprotein‐cholesterol (LDL‐C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controll...

Descripció completa

Dades bibliogràfiques

Autors principals:	Erik Stroes, John R. Guyton, Norman Lepor, Fernando Civeira, Daniel Gaudet, Gerald F. Watts, Marie T. Baccara‐Dinet, Guillaume Lecorps, Garen Manvelian, Michel Farnier, the ODYSSEY CHOICE II Investigators
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2016-09-01
Col·lecció:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Matèries:	alirocumab cardiovascular risk low‐density lipoprotein cholesterol placebo‐controlled proprotein convertase subtilisin/kexin type 9
Accés en línia:	https://doi.org/10.1161/JAHA.116.003421
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!